Literature DB >> 8154312

Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease.

J A Hoyland1, A J Freemont, P T Sharpe.   

Abstract

The cytokine interleukin-6 (IL-6) is considered an important regulator of bone cell function and may play a central role in bone disease states characterized by increased bone remodeling, such as Paget's disease. Indeed, recent in vitro data suggest that IL-6 may be an autocrine/paracrine factor for pagetic osteoclasts. However, its expression and role in vivo are not known. Using in situ hybridization we investigated the spatial localization of expression of IL-6, IL-6 receptor (IL-6R), and the transcription factor (NF-IL-6) in pagetic bone. Our results show that osteoblasts in the normal remodeling bone of osteoarthritis (controls) and in Paget's disease express IL-6, IL-6R, and NF-IL-6 genes with higher levels of IL-6 and IL-6R mRNA in pagetic bone. Osteoclasts in both osteoarthritic and pagetic bone express IL-6R mRNA and NF-IL-6, but only pagetic osteoclasts expressed IL-6, suggesting that in Paget's disease IL-6 can act as an autocrine factor on osteoclasts. These results provide evidence for a major role of the IL-6 regulatory pathway in the phenotype of the pagetic osteoclasts and lead us to suggest a model linking possible paramyxovirus infection and IL-6 regulation in the pagetic osteoclast.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8154312     DOI: 10.1002/jbmr.5650090111

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  22 in total

Review 1.  Paget's disease of bone: diagnosis and treatment update.

Authors:  M Noor; D Shoback
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

Review 2.  Paget's disease of bone: a disease of the osteoclast.

Authors:  S V Reddy; N Kurihara; C Menaa; G D Roodman
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

Review 3.  Treatment of patients with Paget's disease of bone.

Authors:  C Roux; M Dougados
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 4.  Paget disease of bone.

Authors:  G David Roodman; Jolene J Windle
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

5.  Localisation and semiquantitative assessment of hepatic procollagen mRNA in primary biliary cirrhosis.

Authors:  C J Goddard; A Smith; J A Hoyland; P Baird; R F McMahon; A J Freemont; M Shomaf; N Y Haboubi; T W Warnes
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

Review 6.  The contribution of Sir James Paget (1814-1894) to the study of rheumatic disease.

Authors:  W Buchanan
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

Review 7.  Paget's disease of bone.

Authors:  C G Ooi; W D Fraser
Journal:  Postgrad Med J       Date:  1997-02       Impact factor: 2.401

8.  Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management.

Authors:  Joseph L Shaker
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

9.  Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon.

Authors:  R G Hardy; C Tselepis; J Hoyland; Y Wallis; T P Pretlow; I Talbot; D S A Sanders; G Matthews; D Morton; J A Z Jankowski
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

10.  High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy.

Authors:  S Horiuchi; W Ampofo; Y Koyanagi; A Yamashita; M Waki; A Matsumoto; M Yamamoto; N Yamamoto
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.